Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors occurs in nearly all NSCLC patients harboring EGFR-activating mutations (Nilsson et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.